Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Vertex Pharmaceuticals Incorporated (VRTX)

43rd Annual J.P. Morgan Healthcare Conference

January 13, 2025 10:30 AM ET

Company Participants

Dr. Reshma Kewalramani - President and CEO

Charlie Wagner - Chief Financial Officer

Stuart Arbuckle - Chief Operating Officer

David Altshuler - Chief Scientific Officer

Conference Call Participants

Jessica Fye - J.P. Morgan

Presentation

Jessica Fye

Great. Good morning, everyone. Welcome. I'm Jess Fye, Biotech Analyst at J.P. Morgan. We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage t...

SA Transcripts on Seeking Alpha | January 13, 2025

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

BOSTON, January 12, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 a.m. ET/7:30 a.m. PT.

Yahoo | January 12, 2025

Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement

Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore. Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF and APRIL being studied for the treatment of Immunoglobulin A nephropathy and other B cell-mediated diseases. Under the terms of the agreement, Vertex will receive an upfront

Yahoo | January 11, 2025

Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $409.56 in the latest trading session, marking a -0.62% move from the prior day.

Yahoo | January 10, 2025

INCY vs. VRTX: Which Stock Is the Better Value Option?

INCY vs. VRTX: Which Stock Is the Better Value Option?

Yahoo | January 10, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to stock-specific weakness in a handful of holdings and a lack of exposure to several of the top-performing, higher-beta growth companies, the strategy underperformed its benchmark the Russell Mid […]

Yahoo | January 10, 2025

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

SHANGHAI & CAMBRIDGE, Mass. & BOSTON, January 10, 2025--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and

Yahoo | January 10, 2025

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

BOSTON & SHANGHAI & CAMBRIDGE, Mass., January 10, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and

Yahoo | January 10, 2025

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 42% Undervalued

Key Insights Vertex Pharmaceuticals' estimated fair value is US$708 based on 2 Stage Free Cash Flow to Equity Vertex...

Yahoo | January 10, 2025

Vertex and Orna sign partnership to improve efficiencies of gene therapies

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Yahoo | January 8, 2025